Search research articles
Contact Us
Filters
Showing results (21-30 of 35) with videos related to
Page
of 4
Sort By:
Oncogene
|
August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
April 8, 1998
Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3
P L Podolin, P Denny, N Armitage, et al.
Diabetes
|
April 1, 1997
Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene
P Denny, C J Lord, N J Hill, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
September 1, 1995
Mapping the diabetes polygene Idd3 on mouse chromosome 3 by use of novel congenic strains
C J Lord, S K Bohlander, E A Hopes, et al.
Immunity
|
August 10, 2000
The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137
P A Lyons, W W Hancock, P Denny, et al.
British Journal of Cancer
|
September 30, 2010
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
L de Plater, A Laugé, C Guyader, et al.
Oncogene
|
January 22, 2013
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
K-K Shiu, D Wetterskog, A Mackay, et al.
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
S K Sandhu, A Omlin, L Hylands, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 35) with videos related to
Sort By:
Page
of 4
Oncogene
|
August 19, 2007
A chemical inhibitor of PPM1D that selectively kills cells overexpressing PPM1D
S Rayter, R Elliott, J Travers, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
April 8, 1998
Localization of two insulin-dependent diabetes (Idd) genes to the Idd10 region on mouse chromosome 3
P L Podolin, P Denny, N Armitage, et al.
Diabetes
|
April 1, 1997
Mapping of the IDDM locus Idd3 to a 0.35-cM interval containing the interleukin-2 gene
P Denny, C J Lord, N J Hill, et al.
Mammalian Genome : Official Journal of the International Mammalian Genome Society
|
September 1, 1995
Mapping the diabetes polygene Idd3 on mouse chromosome 3 by use of novel congenic strains
C J Lord, S K Bohlander, E A Hopes, et al.
Immunity
|
August 10, 2000
The NOD Idd9 genetic interval influences the pathogenicity of insulitis and contains molecular variants of Cd30, Tnfr2, and Cd137
P A Lyons, W W Hancock, P Denny, et al.
British Journal of Cancer
|
September 30, 2010
Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation
L de Plater, A Laugé, C Guyader, et al.
Oncogene
|
January 22, 2013
Integrative molecular and functional profiling of ERBB2-amplified breast cancers identifies new genetic dependencies
K-K Shiu, D Wetterskog, A Mackay, et al.
The Journal of Pathology
|
September 24, 2008
The genomic profile of HER2-amplified breast cancers: the influence of ER status
C Marchiò, R Natrajan, K K Shiu, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 2, 2020
ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
R E Miller, A Leary, C L Scott, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 26, 2013
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
S K Sandhu, A Omlin, L Hylands, et al.
Page
of 4